Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2870 in gastrointestinal cancers
2023-508703-21-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- Jul 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 13
01
Overview
Phase 2, open-label trial of sacituzumab tirumotecan in colorectal cancer (CRC), pancreatic adenocarcinoma (PDAC) and biliary cancer (2 arms), sponsored by Merck & Co. Primary endpoints: Number of participants who experience a dose-limiting toxicity (DLT), Number of participants who experience one or more adverse events (AEs) and 2 more. Planned start Jul 2024; status: authorised.
02
Drugs
sacituzumab tirumotecan
03
Conditions
colorectal cancer (CRC)pancreatic adenocarcinoma (PDAC)biliary cancer
Beyond the preview
Go deeper on 2023-508703-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508703-21-00.